Ginkgo Bioworks recently announced a $290M Series E financing round from new and prior investors.

HTG Molecular Diagnostics announced recently after the close of the market that it intends to offer an undisclosed amount of its common stock in a public offering.

OncoCyte said recently that it has entered into a definitive agreement to acquire Razor Genomics, which developed and markets a prognostic test to assess risk in early-stage lung cancer patients after surgery.

Microbiology testing and diagnostics firm PathoQuest today announced the closing of an €8 million ($8.9 million) financing round.

Quidel reported after the close of the market Thursday that its second quarter revenues rose 5 percent year over year due primarily to growth in the firm's rapid immunoassay business.

Bio-Rad Laboratories reported after the close of the market Thursday that its second quarter revenues decreased approximately 1 percent year over year.

Coriell Life Sciences and global professional services firm KPMG said today that they have entered into a partnership with to provide pharmacogenomics data to clinicians at the point of care.

Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services.

Expedeon reported today an 18 percent increase in second quarter revenues driven in part by sales generated by recently acquired reagent maker TGR Biosciences.

Bio-Techne said today that its fiscal 2019 fourth quarter revenues rose 6 percent over fiscal Q4 2018.

Becton Dickinson reported a 2 percent year-over-year increase in its fiscal third quarter revenues today.

Aqualung Therapeutics said on Tuesday that it has been awarded a $225,000 grant from the National Institutes of Health to develop a panel of biomarkers, called CRIT-ICU, for stratifying patients at risk for acute respiratory distress syndrome (ARDS).

Cancer Genetics today reported a 15 percent increase in second quarter revenues on improved performance by its core discovery services operations.

Biotechnology company Freenome and ADC Therapeutics, an oncology drug discovery and development company, announced today that they have signed a biomarker development agreement.

Genomenon has entered the Chinese market by forming a partnership with Shanghai Shanyi Biological Technology Co., a provider of sequencing interpretation, variant validation, and other molecular technology services.